Articles related to LIPID MANAGEMENT

Analysis of NHANES data suggests that adoption of the 2026 ACC/AHA dyslipidemia guidelines could make approximately 25 million additional US adults eligible to consider statin therapy, primarily through incorporation of PREVENT risk equations and expanded emphasis on long-term cardiovascular risk.

Adding coronary artery calcium scoring to PREVENT-ASCVD risk equations produced only modest improvements in 10-year ASCVD risk prediction among adults aged 45 to 79 years, with the greatest potential value observed in patients with borderline or intermediate estimated risk.

Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.

A systematic review and meta-analysis found that inclisiran significantly reduced LDL cholesterol compared with placebo across diverse hyperlipidemia populations. Long-term cardiovascular outcome data remain limited despite consistent lipid-lowering efficacy and favorable safety findings.

Discontinuing statins in adults 75 years and older without prior cardiovascular disease did not increase mortality or major cardiovascular events over three years in a randomized trial. LDL cholesterol rose substantially after discontinuation, and longer-term effects remain uncertain.

The 2026 ACC/AHA dyslipidemia guideline reintroduces LDL-C treatment targets, expands risk assessment, and recommends universal Lp(a) screening. New analyses suggest many US adults now exceed recommended cholesterol thresholds, although treatment decisions remain individualized.